RI
CADL icon

RTW Investments’s Candel Therapeutics CADL Stock Holding History

RTW Investments’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$66.1M Hold
6,422,018
– – 0.56% 41
2026
Q1 		$31.5M Buy
+6,422,018
New +$34.9M 0.31% 54

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
HFF
Halter Ferguson Financial Carmel, Indiana $617M AUM 69.99% 1-Year Est. Return

RTW Investments's CADL Position: Q2 2026 in Review

RTW Investments held its Candel Therapeutics (CADL) position steady in Q2 2026 at 6,422,018 shares worth $66.1M. The position accounts for 0.56% of the portfolio, ranked #41.

RTW Investments first reported a position in CADL in Q1 2026 and has held it in 2 quarters since. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • RTW Investments held 6,422,018 shares of Candel Therapeutics worth $66.1M as of Q2 2026.
  • RTW Investments left its Candel Therapeutics share count unchanged in Q2 2026.
  • Candel Therapeutics made up 0.56% of RTW Investments's portfolio in Q2 2026, its #41 holding.
  • RTW Investments first reported a position in Candel Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on RTW Investments's 13F filing for Q2 2026, filed 14 Aug 2026.